2020 could still be further improved. In particular, the most-promising candidate, peptide I5, exhibited a lower stability under a simulated intestinal fluid (SIF) assay and a lower potency for IL-23R in comparison with Protagonist's Compound C (Sayago *et al.*, 2018).

Therefore, there remains a need for new therapeutics targeting the IL-23 pathway, which may be used to treat and prevent IL-23-associated diseases, including those associated with autoimmune inflammation in the intestinal tract. Furthermore, compounds and methods for specific targeting of IL-23R from the luminal side of the gut may provide therapeutic benefit to IBD patients suffering from local inflammation of the intestinal tissue.

The present invention addresses these needs by providing novel peptide inhibitors that bind IL-23R to inhibit IL-23 mediated signalling. The novel peptide inhibitors are also suitable for oral administration due to their stability in the gastrointestinal tract.

SUMMARY

The present disclosure relates to compounds which are peptide inhibitors of interleukin-23 receptor (IL-23R).

In a first aspect, the disclosure provides a compound having the formula:

$$R^1\text{-}Z\text{-}R^2$$

wherein

R^1 is H, $C_{1\text{-}4}$ acyl, benzoyl, $C_{1\text{-}4}$ alkyl, or is absent;

R^2 is NHR^3, OH, or is absent, wherein R^3 is hydrogen or $C_{1\text{-}3}$ alkyl optionally substituted with NH_2; and

Z is an amino acid sequence of formula I:

$$X1\text{-}X2\text{-}X3\text{-}X4\text{-}X5\text{-}X6\text{-}X7\text{-}X8\text{-}X9\text{-}X10\text{-}X11\text{-}X12\text{-}X13\text{-}X14 \qquad (I)$$

wherein

X1 is absent or is selected from the group consisting of Asp, Gly, Leu, Glu, Ser, Cys, and Lys;

X3 is selected from the group consisting of Ser, beta-homo-Ser, Thr, Leu, Cys, Gln, Val, Ile, N-Me-Ser, and Q(pyrrolidin);

In some examples, the disclosure provides a compound having the formula:

$$R^1\text{-}Z\text{-}R^2$$

wherein

R^1 is H, $C_{1\text{-}4}$ acyl, benzoyl, $C_{1\text{-}4}$ alkyl, or is absent;

R^2 is NHR^3, OH, or is absent, wherein R^3 is hydrogen or $C_{1\text{-}3}$ alkyl; and

Z is an amino acid sequence of formula Ia:

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14 (Ia)

wherein

X1 is absent or is selected from the group consisting of Asp, Glu, Ser, Cys, and Lys;

X3 is selected from the group consisting of Ser, beta-homo-Ser, Thr, Leu, Cys, and Gln;

X5 is selected from the group consisting of Trp, Tyr, Ala, 1-Me-Trp, 7-Me-Trp, 7-Ph-Trp, 7-(Naphth-2-yl)-Trp, 2-Nal, and Bip;

X6 is selected from the group consisting of Gln, Glu, Tyr and Cys;

X8 is selected from the group consisting of Trp, Tyr, Asn, Ala, His, and 2-Nal, wherein the hydroxyl group of Tyr is optionally substituted with $C_{1\text{-}3}$ alkyl optionally substituted with NH_2;

X9 is selected from the group consisting of 2-Nal, Trp, 1-Me-Trp, 6-Cl-Trp, 3-(3-Quinolinyl)-Ala, Phe, 4-F-Phe, Glu, Cys, and Ala;

X10 is selected from the group consisting of Leu, D-Leu, 2-Me-Leu, 2-Me-Lys, Trp, Asn, Cys, and 4-aminotetrahydro-2H-pyran-4-acetyl;

X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent;

X13 is absent or is selected from the group consisting of Asn, Gly, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala;

X14 is absent or is Gly;

X2 and X11 are amino acid residues who together form a lactam bridge, a dithioether bridge, or a bridge containing a triazole ring; and

X4 and X7 are amino acid residues who together form a lactam bridge, a dithioether bridge, or a bridge containing a triazole ring;

or a pharmaceutically acceptable salt or solvate thereof.

In some examples, the compound is not:

I3 (isomer 3) H-DC(1a)SC(2a)WQC(2a)WWLC(1a)R-[NH2];

wherein (1a) is a [2,11] 1,3-dithio-propan-2-one bridge and (2a) is a [4,7] 1,3-dithio-propan-2-one bridge.

In some examples, the compound is not:

I3 (isomer 3) H-DC(1a)SC(2a)WQC(2a)WWLC(1a)R-OH;

wherein (1a) is a [2,11] 1,3-dithio-propan-2-one bridge and (2a) is a [4,7] 1,3-dithio-propan-2-one bridge.

In some examples, Z is not:

I3 (isomer 3) DC(1a)SC(2a)WQC(2a)WWLC(1a)R;

wherein (1a) is a [2,11] 1,3-dithio-propan-2-one bridge and (2a) is a [4,7] 1,3-dithio-propan-2-one bridge.

In some examples, the bridge in X2 and X11 and the bridge in X4 and X7 are not both 1,3-dithio-propan-2-one bridges.

In some examples, the bridge in X2 and X11 and the bridge in X4 and X7 are not both dithioether bridges.

In some examples, X1 is absent or Asp.

In some examples, X1 is absent.

In some examples, X3 is Ser or Ile.

In some examples, X3 is Ser.

In some examples, X5 is Trp or 7-Me-Trp.

In some examples, X5 is Trp.

In some examples, X6 is Gln or Glu.

In some examples, X6 is Gln.

In some examples, X8 is Trp, Tyr, or 4-Me-Phe; wherein the hydroxyl group of Tyr is optionally substituted with $-CH_2CH_2NH_2$.

In some examples, X8 is Tyr wherein the hydroxyl group of Tyr is optionally substituted with $-CH_2CH_2NH_2$.

In some examples, X9 is 2-Nal, Trp, or 3,4-Me-Phe.

In some examples, X9 is 2-Nal or Trp.

In some examples, X9 is 2-Nal.

In some examples, X10 is Leu, 2-Me-Leu, or 2-Me-Val.

In some examples, X10 is Leu or 2-Me-Leu.

In some examples, X10 is Leu.

In some examples, X12 is Arg, D-Arg, and Dab.

In some examples, X12 is Arg.

In some examples, X13 is absent, 3-(3-Pyridyl)-Ala, or 2-Me-3-(3-Pyridyl)-Ala.

In some examples, X13 is absent.

In some examples, X14 is absent.

In some examples, R^1 is H, C_{1-2} acyl, or is absent.

In some examples, R^1 is absent.

In some examples, R^1 is -C(=O)CH_3.

In some examples, R^2 is NH_2.

In some examples, the length of the bridge between X2 and X11 and/or X4 and X7 is 5 to 10 atoms long.

In some examples, X1 is absent, R^1 is absent, and X2 and X11 are amino acid residues that together form a lactam bridge or a bridge containing a triazole ring via the *N*-terminus of X2.

In some examples, X1 and X12 to X14 are absent, R^1 and R^2 are absent, and X2 and X11 are amino acid residues that together form a head-to-tail cyclised lactam bridge via the *N*-terminus of X2 and the *C*-terminus of X11.

In some examples, the dithioether bridge between X2 and X11 and/or X4 and X7 is of the formula -S-L-Y-L-S-, wherein:

each S is a sulfur atom and is part of the amino acid residue at X2 and X11 and/or X4 and X7;

each L is independently C_{1-4} alkylene; and

Y is either absent, C(=O), or arylene.

In some examples, each L is independently C_{1-2} alkylene.

In some examples, each L is methylene.

In some examples, Y is C(=O).

In some examples, Y is arylene selected from phenylene.

In some examples, Y is phenylene selected from 1,2-phenylene, 1,3-phenylene, and 1,4-phenylene.

In some examples, Y is 1,2-phenylene.

In some examples, the bridge containing a triazole ring between X2 and X11 and/or X4 and X7 contains a 1,2,3-triazole ring.

In some examples, the bridge containing a triazole ring between X2 and X11 and/or X4 and X7 is attached to positions 1 and 4 of the triazole ring.

In some examples, the bridge containing a triazole ring between X2 and X11 and/or X4 and X7 is attached to positions 1 and 5 of the triazole ring.

In some examples, X2 and X11 are amino acid residues who together form a lactam bridge.

In some examples, the location of the amide bond in the lactam bridge is closer to X11 than X2.

In some examples, one of the residues at position X2 and X11 is selected from Lys, Arg, Orn, bAla, 3-(4-aminophenyl)propanoyl, (3-aminomethyl)benzoyl, (4-aminomethyl)benzoyl, 4-(2-aminoethyl)benzoyl, 2-aminomethyl-phenylacetyl, 3-aminomethyl-phenylacetyl, 4-aminomethyl-phenylacetyl, 4-aminomethyl-2-pyridineacetyl, 4-aminomethyl-3-pyridineacetyl, 4-aminomethyl-2-fluoro-phenylacetyl, 4-aminomethyl-3-fluoro-phenylacetyl, 4-aminomethyl-2-methyl-phenylacetyl, 4-aminomethyl-3-methyl-phenylacetyl, 4-aminomethyl-2-methoxy-phenylacetyl, 4-aminomethyl-3-methoxy-phenylacetyl, Dab, 6-aminohexanoyl, 6-amino-4-oxahexanoyl, trans-4-aminomethyl-cyclohexyl-1-carbonyl, (4-(2-aminoethyl)-piperazine-1-yl)-acetyl, 2,4-diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl), and 4-methylaminomethyl-phenylacetyl, and the other is selected from Glu and Asp.

In some examples, X2 is selected from Lys, Orn, bAla, 3-(4-aminophenyl)propanoyl, (3-aminomethyl)benzoyl, (4-aminomethyl)benzoyl, 4-(2-aminoethyl)benzoyl, 2-aminomethyl-phenylacetyl, 3-aminomethyl-phenylacetyl, 4-aminomethyl-phenylacetyl, 4-aminomethyl-2-pyridineacetyl, 4-aminomethyl-3-pyridineacetyl, 4-aminomethyl-2-fluoro-phenylacetyl, 4-aminomethyl-3-fluoro-phenylacetyl, 4-aminomethyl-2-methyl-phenylacetyl, 4-aminomethyl-3-methyl-phenylacetyl, 4-aminomethyl-2-methoxy-phenylacetyl, 4-aminomethyl-3-methoxy-phenylacetyl, 6-aminohexanoyl, 6-amino-4-oxahexanoyl, trans-4-

aminomethyl-cyclohexyl-1-carbonyl, (4-(2-aminoethyl)-piperazine-1-yl)-acetyl, 2,4-diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl), and 4-methylaminomethyl-phenylacetyl, and X11 is Glu and Asp.

In some examples, X2 is Lys and X11 is Glu; X2 is Orn and X11 is Glu; X2 is bAla and X11 is Glu; X2 is 3-(4-aminophenyl)propanoyl and X11 is Glu; X2 is (3-aminomethyl)benzoyl and X11 is Glu; X2 is (4-aminomethyl)benzoyl and X11 is Glu; X2 is 4-(2-aminoethyl)benzoyl and X11 is Glu; X2 is 2-aminomethyl-phenylacetyl and X11 is Glu; X2 is 3-aminomethyl-phenylacetyl and X11 is Glu; X2 is 4-aminomethyl-phenylacetyl and X11 is Glu; X2 is 6-aminohexanoyl and X11 is Glu; X2 is 6-amino-4-oxahexanoyl and X11 is Glu; X2 is trans-4-aminomethyl-cyclohexyl-1-carbonyl and X11 is Glu; X2 is (4-(2-aminoethyl)-piperazine-1-yl)-acetyl and X11 is Glu; X2 is (4-(2-aminoethyl)-piperazine-1-yl)-acetyl and X11 is Asp; X2 is 4-aminomethyl-2-pyridineacetyl and X11 is Glu; X2 is 4-aminomethyl-3-pyridineacetyl and X11 is Glu; X2 is 4-aminomethyl-2-fluoro-phenylacetyl and X11 is Glu; X2 is 4-aminomethyl-3-fluoro-phenylacetyl and X11 is Glu; X2 is 4-aminomethyl-2-methyl-phenylacetyl and X11 is Glu; X2 is 4-aminomethyl-3-methyl-phenylacetyl and X11 is Glu; X2 is 4-aminomethyl-2-methoxy-phenylacetyl and X11 is Glu; X2 is 4-aminomethyl-3-methoxy-phenylacetyl and X11 is Glu; X2 is Dab and X11 is Glu; X2 is 2,4-diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl) and X11 is Glu; or X2 is 2,4-diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl) and X11 is Glu.

In some examples, X2 is Lys and X11 is Glu; X2 is (3-aminomethyl)benzoyl and X11 is Glu; or X2 is 4-aminomethyl-phenylacetyl and X11 is Glu.

In some examples, X2 is Lys and X11 is Glu.

In some examples, X2 is selected from Glu and Asp, and X11 is selected from Lys, Arg, and Dab.

In some examples, X2 is Glu and X11 is Lys; X2 is Glu and X11 is Dab; or X2 is Asp and X11 is Arg.

In some examples, X2 and X11 are amino acid residues who together form a dithioether bridge.

In some examples, X2 and X11 are each independently selected from Cys and N-Me-Cys.

In some examples, X2 is Cys and X11 is Cys.

In some examples, X2 and X11 are amino acid residues who together form a bridge containing a triazole ring.

In some examples, one of the residues at position X2 and X11 is selected from Lys(N_3), azidoacetic acid, (N_3)-Ala, Dab(azidoacetic acid), and the other is selected from Pra, Glu(propargylamine), Dab(3-butynoic acid), and but-3-ynoic acid.

In some examples, X2 is selected from Lys(N_3), azidoacetic acid, and (N_3)-Ala; and X11 is selected from Pra, Glu(propargylamine), and Dab(3-butynoic acid).

In some examples, X2 is Lys(N_3) and X11 is Pra; X2 is azidoacetic acid and X11 is Glu(propargylamine); X2 is azidoacetic acid and X11 is Dab(3-butynoic acid); X2 is (N_3)-Ala and X11 is Glu(propargylamine); or X2 is (N_3)-Ala and X11 is Dab(3-butynoic acid).

In some examples, X2 is Lys(N_3) and X11 is Pra.

In some examples, X2 is selected from Pra, and but-3-ynoic acid; and X11 is selected from Dab(azidoacetic acid), and Dab((N_3)-Ala).

In some examples, X2 is Pra and X11 is Dab(azidoacetic acid); X2 is Pra and X11 is Dab((N_3)-Ala); X2 is but-3-ynoic acid and X11 is Dab(azidoacetic acid); or X2 is but-3-ynoic acid and X11 is Dab((N_3)-Ala). In some examples, X2 is Pra and X11 is Dab(azidoacetic acid); or X2 is Pra and X11 is Dab((N_3)-Ala). In some examples, X2 is but-3-ynoic acid and X11 is Dab(azidoacetic acid); or X2 is but-3-ynoic acid and X11 is Dab((N_3)-Ala).

In some examples, X4 and X7 are amino acid residues who together form a dithioether bridge.

In some examples, X4 and X7 are each independently selected from Cys and N-Me-Cys.

In some examples, X4 is Cys and X7 is Cys; or X4 is N-Me-Cys and X7 is Cys.

In some examples, X4 is Cys and X7 is Cys.

In some examples, X4 and X7 are amino acid residues who together form a lactam bridge.

In some examples, one of the residues at position X4 and X7 is Lys, Dpr, Dab, or Orn, and the other is Glu.

In some examples, X4 is selected from Lys, Dpr, Dab, and Orn, and X7 is Glu.

In some examples, X4 is Dpr and X7 is Glu; X4 is Dab and X7 is Glu; or X4 is Orn and X7 is Glu.

In some examples, X4 is Glu, and X7 is selected from Lys, Dpr, Dab, and Orn.

In some examples, X4 is Glu and X7 is Lys; X4 is Glu and X7 is Dpr; X4 is Glu and X7 is Orn; or X4 is Glu and X7 is Dab.

In some examples, X4 and X7 are amino acid residues who together form a bridge containing a triazole ring.

In some examples, one of the residues at position X4 and X7 is selected from Lys(N_3) and Aha, and the other is Pra.

In some examples, X4 is Lys(N_3) and X7 is Pra; or X4 is Aha and X7 is Pra.

In some examples, X8 is Trp; X10 is D-Leu; and X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent.

In some examples, X8 is Tyr wherein the hydroxyl group of Tyr is optionally substituted with C_{1-3} alkyl optionally substituted with NH_2; X10 is D-Leu; and X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent.

In some examples, X8 is Asn; X10 is D-Leu; and X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent.

In some examples, X8 is Ala; X10 is D-Leu; and X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent.

In some examples, X8 is His; X10 is D-Leu; and X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent.

In some examples, X8 is 2-Nal; X10 is D-Leu; and X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent.

In some examples, X8 is Tyr wherein the hydroxyl group of Tyr is optionally substituted with -$CH_2CH_2NH_2$; X10 is 2-Me-Leu; and X12 is Arg or is absent.

In some examples, X8 is Trp; X10 is 2-Me-Leu; and X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent.

In some examples, X8 is Tyr wherein the hydroxyl group of Tyr is optionally substituted with C_{1-3} alkyl optionally substituted with NH_2; X10 is 2-Me-Leu; and X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent.

In some examples, X8 is Asn; X10 is 2-Me-Leu; and X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent.

In some examples, X8 is Ala; X10 is 2-Me-Leu; and X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent.

In some examples, X8 is His; X10 is 2-Me-Leu; and X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent.

In some examples, X8 is 2-Nal; X10 is 2-Me-Leu; and X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent.

In some examples, X8 is Tyr wherein the hydroxyl group of Tyr is optionally substituted with -$CH_2CH_2NH_2$; X10 is D-Leu; and X12 is Arg or is absent.

In some examples, X8 is Tyr wherein the hydroxyl group of Tyr is optionally substituted with -$CH_2CH_2NH_2$; X10 is 2-Me-Leu; and X12 is Arg or is absent.

In some examples, Z is an amino acid sequence selected from the group consisting of:

SEQ ID NO: 1	DC(1a)SC(2a)WQC(2a)WW[2-Me-Leu]C(1a)R
SEQ ID NO: 2	LC(1a)SC(2a)WQC(2a)WWLC(1a)R
SEQ ID NO: 3	DC(1a)SC(2a)WEC(2a)WWLC(1a)R
SEQ ID NO: 4	DE(1c)SC(2a)WQC(2a)WWLK(1c)R
SEQ ID NO: 5	DC(1a)SE(2c)WQK(2c)WWLC(1a)R
SEQ ID NO: 6	D(1c)*SC(2a)WQC(2a)WWLR(1c)*
SEQ ID NO: 7	DK(1c)SC(2a)WQC(2a)WWLE(1c)R
SEQ ID NO: 8	D[Orn](1c)SC(2a)WQC(2a)WWLE(1c)R
SEQ ID NO: 9	DE(1c)SC(2a)WQC(2a)WWL[Dab](1c)R
SEQ ID NO: 10	E(1c)SC(2a)WQC(2a)WWLK(1c)R
SEQ ID NO: 11	DE(1c)SC(2a)WQC(2a)WWLK(1c)
SEQ ID NO: 12	E(1c)SC(2a)WQC(2a)WWLK(1c)
SEQ ID NO: 13	DE(1c)SC(2a)AQC(2a)WWLK(1c)R
SEQ ID NO: 14	DE(1c)SC(2a)WQC(2a)AWLK(1c)R
SEQ ID NO: 15	DE(1c)SC(2a)WQC(2a)WALK(1c)R
SEQ ID NO: 16	DE(1c)SC(2a)[7-Me-Trp]QC(2a)WWLK(1c)R
SEQ ID NO: 17	DE(1c)SC(2a)WQC(2a)W[2-Nal]LK(1c)R
SEQ ID NO: 18	K(1c)SC(2a)WQC(2a)W[2-Nal]LE(1c)R

(1a) = [2,11] 1,3-dithio-propan-2-one bridge; (1c) = [2,11] lactam bridge; (1g) = [2,11] 1,4-disubstituted 1,2,3-triazole bridge; (2a) = [4,7] 1,3-dithio-propan-2-one bridge; (2c) = [4,7] lactam bridge; (2d) = [4,7] 1,2-phenylenedimethanethiol bridge; (2e) = [4,7] 1,3-phenylenedimethanethiol bridge; (2f) = [4,7] 1,4-phenylenedimethanethiol bridge; (2g) = [4,7] 1,4-disubstituted 1,2,3-triazole bridge.

In some examples, Z is an amino acid sequence selected from the group consisting of:

SEQ ID NO: 106	[but-3-ynoic acid](1h)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab(azidoacetic acid)](1h)[{d}R]
SEQ ID NO: 107	[but-3-ynoic acid](1h)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab((N_3)-Ala)](1h)[{d}R]
SEQ ID NO: 108	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 109	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}2,4-Diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl)]
SEQ ID NO: 110	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Dab][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 111	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[2,4-Diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 112	[Dab](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 113	[2,4-Diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl)](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 114	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[F(4-NH2-(2-(trimethyl-2-aminoethoxy)ethoxy)propyl)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 115	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}Q]
SEQ ID NO: 116	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}E]
SEQ ID NO: 117	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}H]
SEQ ID NO: 118	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-Aminopropanoyl]

SEQ ID NO: 176 [4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][Bip][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]

SEQ ID NO: 177 [4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][{d}6-F-Trp][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]

or a pharmaceutically acceptable salt or solvate thereof;

wherein:

* = bridge uses the peptide backbone amine or carboxylic acid at the *N*- or *C*-terminus, not the side chain amine or carboxylic acid

(1a) = [2,11] 1,3-dithio-propan-2-one bridge; (1c) = [2,11] lactam bridge; (1g) = [2,11] 1,4-disubstituted 1,2,3-triazole bridge; (1h) = [2,11] 1,5-disubstituted 1,2,3-triazole bridge; (2a) = [4,7] 1,3-dithio-propan-2-one bridge; (2c) = [4,7] lactam bridge; (2d) = [4,7] 1,2-phenylenedimethanethiol bridge; (2e) = [4,7] 1,3-phenylenedimethanethiol bridge; (2f) = [4,7] 1,4-phenylenedimethanethiol bridge; (2g) = [4,7] 1,4-disubstituted 1,2,3-triazole bridge.

In some examples, Z is an amino acid sequence selected from the group consisting of:

SEQ ID NO: 1 DC(1a)SC(2a)WQC(2a)WW[2-Me-Leu]C(1a)R

SEQ ID NO: 2 LC(1a)SC(2a)WQC(2a)WWLC(1a)R

SEQ ID NO: 3 DC(1a)SC(2a)WEC(2a)WWLC(1a)R

SEQ ID NO: 4 DE(1c)SC(2a)WQC(2a)WWLK(1c)R

SEQ ID NO: 5 DC(1a)SE(2c)WQK(2c)WWLC(1a)R

SEQ ID NO: 6 D(1c)*SC(2a)WQC(2a)WWLR(1c)*

SEQ ID NO: 9 DE(1c)SC(2a)WQC(2a)WWL[Dab](1c)R

SEQ ID NO: 10 E(1c)SC(2a)WQC(2a)WWLK(1c)R

SEQ ID NO: 11 DE(1c)SC(2a)WQC(2a)WWLK(1c)

SEQ ID NO: 12 E(1c)SC(2a)WQC(2a)WWLK(1c)

SEQ ID NO: 13 DE(1c)SC(2a)AQC(2a)WWLK(1c)R

SEQ ID NO: 14 DE(1c)SC(2a)WQC(2a)AWLK(1c)R

* = bridge uses the peptide backbone amine or carboxylic acid at the *N*- or *C*-terminus, not the side chain amine or carboxylic acid

(1a) = [2,11] 1,3-dithio-propan-2-one bridge; (1c) = [2,11] lactam bridge; (1g) = [2,11] 1,4-disubstituted 1,2,3-triazole bridge; (2a) = [4,7] 1,3-dithio-propan-2-one bridge; (2c) = [4,7] lactam bridge; (2d) = [4,7] 1,2-phenylenedimethanethiol bridge; (2e) = [4,7] 1,3-phenylenedimethanethiol bridge; (2f) = [4,7] 1,4-phenylenedimethanethiol bridge; (2g) = [4,7] 1,4-disubstituted 1,2,3-triazole bridge.

In some examples, Z is an amino acid sequence selected from the group consisting of:

SEQ ID NO: 67	[(3-Aminomethyl)benzoyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 68	[(3-Aminomethyl)benzoyl](1c)*S[Orn](2c)WQE(2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 69	[(3-Aminomethyl)benzoyl](1c)*SE(2c)WQ[Orn](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 70	[(3-Aminomethyl)benzoyl](1c)*SC(2a)[7-Me-Trp]QC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 78	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[3-(3-Pyridyl)-Ala]
SEQ ID NO: 79	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[3-(4-Pyridyl)-Ala]
SEQ ID NO: 80	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 81	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)S
SEQ ID NO: 82	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 84	[Ac]-K(1c)SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 85	[Ac]-K(1c)TC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 87	[6-Aminohexanoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 90	[(4-(2-Aminoethyl)-piperazine-1-yl)-acetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]

SEQ ID NO: 92	[3-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]

or a pharmaceutically acceptable salt or solvate thereof;

wherein:

* = bridge uses the peptide backbone amine or carboxylic acid at the *N*- or *C*-terminus, not the side chain amine or carboxylic acid

(1a) = [2,11] 1,3-dithio-propan-2-one bridge; (1c) = [2,11] lactam bridge; (1g) = [2,11] 1,4-disubstituted 1,2,3-triazole bridge; (2a) = [4,7] 1,3-dithio-propan-2-one bridge; (2c) = [4,7] lactam bridge; (2d) = [4,7] 1,2-phenylenedimethanethiol bridge; (2e) = [4,7] 1,3-phenylenedimethanethiol bridge; (2f) = [4,7] 1,4-phenylenedimethanethiol bridge; (2g) = [4,7] 1,4-disubstituted 1,2,3-triazole bridge.

In some examples, Z is an amino acid sequence selected from the group consisting of:

SEQ ID NO: 108	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 109	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}2,4-Diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl)]
SEQ ID NO: 115	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}Q]
SEQ ID NO: 117	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}H]
SEQ ID NO: 119	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-Aminopropanoyl]
SEQ ID NO: 120	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]
SEQ ID NO: 121	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][6-F-Trp][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]
SEQ ID NO: 122	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]
SEQ ID NO: 123	[4-Aminomethyl-phenylacetyl](1c)*S[Dab](2c)WQE(2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]

Specific compounds of the disclosure include:

Compound No.	Sequence
1	H-DC(1a)SC(2a)WQC(2a)WW[2-Me-Leu]C(1a)R-[NH2]
2	H-LC(1a)SC(2a)WQC(2a)WWLC(1a)R-[NH2]
3	H-DC(1a)SC(2a)WEC(2a)WWLC(1a)R-[NH2]
4	H-DE(1c)SC(2a)WQC(2a)WWLK(1c)R-[NH2]
5	H-DC(1a)SE(2c)WQK(2c)WWLC(1a)R-[NH2]
6	D(1c)*SC(2a)WQC(2a)WWLR(1c)*
7	[Ac]-DK(1c)SC(2a)WQC(2a)WWLE(1c)R-[NH2]
8	[Ac]-D[Orn](1c)SC(2a)WQC(2a)WWLE(1c)R-[NH2]
9	H-DE(1c)SC(2a)WQC(2a)WWL[Dab](1c)R-[NH2]
10	[Ac]-E(1c)SC(2a)WQC(2a)WWLK(1c)R-[NH2]
11	[Ac]-DE(1c)SC(2a)WQC(2a)WWLK(1c)-[NH2]
12	[Ac]-E(1c)SC(2a)WQC(2a)WWLK(1c)-[NH2]
13	[Ac]-DE(1c)SC(2a)AQC(2a)WWLK(1c)R-[NH2]
14	[Ac]-DE(1c)SC(2a)WQC(2a)AWLK(1c)R-[NH2]
15	[Ac]-DE(1c)SC(2a)WQC(2a)WALK(1c)R-[NH2]
16	[Ac]-DE(1c)SC(2a)[7-Me-Trp]QC(2a)WWLK(1c)R-[NH2]
17	[Ac]-DE(1c)SC(2a)WQC(2a)W[2-Nal]LK(1c)R-[NH2]

Compound No.	Sequence
104	[4-Aminomethyl-3-methyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
105	[4-Aminomethyl-3-methoxy-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]

and pharmaceutically acceptable salts and solvates thereof;

wherein:

* = bridge uses the peptide backbone amine or carboxylic acid at the *N*- or *C*-terminus, not the side chain amine or carboxylic acid

(1a) = [2,11] 1,3-dithio-propan-2-one bridge; (1c) = [2,11] lactam bridge; (1g) = [2,11] 1,4-disubstituted 1,2,3-triazole bridge; (2a) = [4,7] 1,3-dithio-propan-2-one bridge; (2c) = [4,7] lactam bridge; (2d) = [4,7] 1,2-phenylenedimethanethiol bridge; (2e) = [4,7] 1,3-phenylenedimethanethiol bridge; (2f) = [4,7] 1,4-phenylenedimethanethiol bridge; (2g) = [4,7] 1,4-disubstituted 1,2,3-triazole bridge.

Other specific compounds of the disclosure include:

Compound No.	Sequence
106	[but-3-ynoic acid](1h)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab(azidoacetic acid)](1h)[{d}R]-[NH2]
107	[but-3-ynoic acid](1h)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab((N_3)-Ala))](1h)[{d}R]-[NH2]
108	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[OH]
109	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}2,4-Diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl)]-[NH2]

Compound No.	Sequence
175	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][1-Me-Trp][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
176	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][Bip][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
177	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][{d}6-F-Trp][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]

and pharmaceutically acceptable salts and solvates thereof;

* = bridge uses the peptide backbone amine or carboxylic acid at the *N*- or *C*-terminus, not the side chain amine or carboxylic acid

(1a) = [2,11] 1,3-dithio-propan-2-one bridge; (1c) = [2,11] lactam bridge; (1g) = [2,11] 1,4-disubstituted 1,2,3-triazole bridge; (1h) = [2,11] 1,5-disubstituted 1,2,3-triazole bridge; (2a) = [4,7] 1,3-dithio-propan-2-one bridge; (2c) = [4,7] lactam bridge; (2d) = [4,7] 1,2-phenylenedimethanethiol bridge; (2e) = [4,7] 1,3-phenylenedimethanethiol bridge; (2f) = [4,7] 1,4-phenylenedimethanethiol bridge; (2g) = [4,7] 1,4-disubstituted 1,2,3-triazole bridge.

In some examples, specific compounds of the disclosure include:

Compound No.	Sequence
1	H-DC(1a)SC(2a)WQC(2a)WW[2-Me-Leu]C(1a)R-[NH2]
2	H-LC(1a)SC(2a)WQC(2a)WWLC(1a)R-[NH2]
3	H-DC(1a)SC(2a)WEC(2a)WWLC(1a)R-[NH2]
4	H-DE(1c)SC(2a)WQC(2a)WWLK(1c)R-[NH2]
5	H-DC(1a)SE(2c)WQK(2c)WWLC(1a)R-[NH2]

60	[Ac]-DE(1c)SC(2a)WQC(2a)W[2-Nal][2-Me-Leu]K(1c)G-[NH2]
61	[Ac]-DE(1c)SC(2a)WQC(2a)W[2-Nal][2-Me-Lys]K(1c)ENG-[NH2]
62	[Ac]-DC(1a)QC(2a)WQC(2a)[2-Nal]W[2-Me-Leu]C(1a)R-[NH2]
63	[Ac]-DC(1a)QC(2a)WQC(2a)YW[2-Me-Leu]C(1a)R-[NH2]
64	[Ac]-DC(1a)QC(2a)WQC(2a)WW[2-Me-Leu]C(1a)ENG-[NH2]

and pharmaceutically acceptable salts and solvates thereof;

wherein:

* = bridge uses the peptide backbone amine or carboxylic acid at the *N*- or *C*-terminus, not the side chain amine or carboxylic acid

(1a) = [2,11] 1,3-dithio-propan-2-one bridge; (1c) = [2,11] lactam bridge; (1g) = [2,11] 1,4-disubstituted 1,2,3-triazole bridge; (2a) = [4,7] 1,3-dithio-propan-2-one bridge; (2c) = [4,7] lactam bridge; (2d) = [4,7] 1,2-phenylenedimethanethiol bridge; (2e) = [4,7] 1,3-phenylenedimethanethiol bridge; (2f) = [4,7] 1,4-phenylenedimethanethiol bridge; (2g) = [4,7] 1,4-disubstituted 1,2,3-triazole bridge.

In some examples, specific compounds of the disclosure include:

Compound No.	**Sequence**
67	[(3-Aminomethyl)benzoyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
68	[(3-Aminomethyl)benzoyl](1c)*S[Orn](2c)WQE(2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
69	[(3-Aminomethyl)benzoyl](1c)*SE(2c)WQ[Orn](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]

phenylenedimethanethiol bridge; (2f) = [4,7] 1,4-phenylenedimethanethiol bridge; (2g) = [4,7] 1,4-disubstituted 1,2,3-triazole bridge.

In some examples, specific compounds of the disclosure include:

Compound No.	Sequence
108	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[OH]
109	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}2,4-Diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl)]-[NH2]
115	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}Q]-[NH2]
117	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}H]-[NH2]
119	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-Aminopropanoyl]-[NH2]
120	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]
121	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][6-F-Trp][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]
122	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]
123	[4-Aminomethyl-phenylacetyl](1c)*S[Dab](2c)WQE(2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]
124	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Orn](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]

175	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][1-Me-Trp][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
176	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][Bip][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
177	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][{d}6-F-Trp][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]

and pharmaceutically acceptable salts and solvates thereof;

wherein:

* = bridge uses the peptide backbone amine or carboxylic acid at the *N*- or *C*-terminus, not the side chain amine or carboxylic acid

(1a) = [2,11] 1,3-dithio-propan-2-one bridge; (1c) = [2,11] lactam bridge; (1g) = [2,11] 1,4-disubstituted 1,2,3-triazole bridge; (1h) = [2,11] 1,5-disubstituted 1,2,3-triazole bridge; (2a) = [4,7] 1,3-dithio-propan-2-one bridge; (2c) = [4,7] lactam bridge; (2d) = [4,7] 1,2-phenylenedimethanethiol bridge; (2e) = [4,7] 1,3-phenylenedimethanethiol bridge; (2f) = [4,7] 1,4-phenylenedimethanethiol bridge; (2g) = [4,7] 1,4-disubstituted 1,2,3-triazole bridge.

The disclosure further provides a composition comprising a compound as described above. The composition may be a pharmaceutical composition, and may comprise a pharmaceutically acceptable carrier, excipient or vehicle.

The disclosure further provides a method for the synthesis of a compound as described above. The method may comprise the steps of synthesising the peptide by solid-phase or liquid-phase methodology, and optionally isolating and/or purifying the final product, and optionally further comprising the step of forming an amide bond, forming two thioether bonds with a linker, or forming a triazole between the amino acid residues at positions X2 and X11, and optionally further comprising the step of forming an amide bond, forming two thioether bonds with a linker, or forming a triazole between the amino acid residues at positions X4 and X7.

The disclosure further provides a compound of the disclosure, or a pharmaceutical compositions comprising said compound, for use in a method of medical treatment.

The disclosure also provides a compound of the disclosure, or a pharmaceutical composition comprising said compound, for use in a method of prevention or treatment of Inflammatory Bowel Disease (IBD), ulcerative colitis, Crohn's disease, Celiac disease (nontropical Sprue), enteropathy associated with seronegative arthropathies, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-I, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, and Wiskott-Aldrich Syndrome, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, psoriasis, psoriatic arthritis, ankylosing spondylitis, or graft versus host disease in a subject, and combinations thereof.

In some examples, the compound of the disclosure, or the pharmaceutical composition comprising said compound, for use in a method of prevention or treatment of inflammatory bowel (IBD), Crohn’s Disease, ulcerative colitis, and psoriasis.

The disclosure also provides use of a compound of the disclosure, or the pharmaceutical composition comprising said compound, in the manufacture of a medicament for the prevention or treatment of Inflammatory Bowel Disease (IBD), ulcerative colitis, Crohn's disease, Celiac disease (nontropical Sprue), enteropathy associated with seronegative arthropathies, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-I, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, and Wiskott-Aldrich Syndrome, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, psoriasis, psoriatic arthritis, ankylosing spondylitis, or graft versus host disease in a subject, and combinations thereof.

In some examples, the use of the compound of the disclosure, or the pharmaceutical composition comprising said compound, in the manufacture of a medicament for the prevention or treatment of inflammatory bowel (IBD), Crohn’s Disease, ulcerative colitis, and psoriasis.

The disclosure also provides a method of prevention or treatment of Inflammatory Bowel Disease (IBD), ulcerative colitis, Crohn's disease, Celiac disease (nontropical Sprue), enteropathy associated with seronegative arthropathies, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-I, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, and Wiskott-Aldrich Syndrome, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, psoriasis, psoriatic arthritis, ankylosing spondylitis, or graft versus host disease in a subject, and combinations thereof; which comprises administering to a subject an effective amount of a compound of the disclosure, or a pharmaceutical composition comprising said compound.

In some examples, the method of prevention or treatment of inflammatory bowel (IBD), Crohn’s Disease, ulcerative colitis, and psoriasis; which comprises administering to the subject an effective amount of the compound of the disclosure, or the pharmaceutical composition comprising said compound.

Further aspects and examples of the present disclosure will become apparent from the disclosure below.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

Unless otherwise defined herein, scientific and technical terms used herein shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature employed herein in connection with techniques of chemistry, molecular biology, cell and cancer biology, immunology, microbiology, pharmacology, and protein and nucleic acid chemistry, described herein, is that well known and commonly used in the art.

All publications, patents and published patent applications referred to in this application are specifically incorporated by reference herein. In case of conflict, the present specification, including its specific definitions, will control.

Throughout this specification, the word “comprise” or variations such as “comprises” or “comprising” will be understood to imply the inclusion of a stated integer or component, or

CLAIMS

1. A compound of the formula:

$$R^1\text{-}Z\text{-}R^2$$

wherein

R^1 is H, $C_{1\text{-}4}$ acyl, benzoyl, $C_{1\text{-}4}$ alkyl, or is absent;

R^2 is NHR^3, OH, or is absent, wherein R^3 is hydrogen or $C_{1\text{-}3}$ alkyl optionally substituted with NH_2; and

Z is an amino acid sequence of formula I:

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14 (I)

wherein

X1 is absent or is selected from the group consisting of Asp, Gly, Leu, Glu, Ser, Cys, and Lys;

X3 is selected from the group consisting of Ser, beta-homo-Ser, Thr, Leu, Cys, Gln, Val, Ile, N-Me-Ser, and Q(pyrrolidin);

X5 is selected from the group consisting of Trp, Tyr, Ala, 1-Me-Trp, 7-Me-Trp, 7-Ph-Trp, 7-(Naphth-2-yl)-Trp, 2-Nal, Bip, 4-F-Trp, 7-F-Trp, and N-Me-Trp;

X6 is selected from the group consisting of Gln, Glu, Tyr, Cys, Val, His, N-Me-Gln, and Q(pyrrolidin);

X8 is selected from the group consisting of Trp, Tyr, Asn, Ala, His, 2-Nal, Dab, 2,4-diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl), F(4-NH_2-(2-(trimethyl-2-aminoethoxy)ethoxy)propyl), Phe, Val, 4-Me-Phe, 2-Me-Phe, Bip, 2-Me-F(4-F), {d}F(4-F), 4-Cl-Phe, alpha-Me-Trp, 3,3-Diphenyl-Ala, and Phg, wherein the hydroxyl group of Tyr is optionally substituted with $C_{1\text{-}3}$ alkyl optionally substituted with NH_2;

X9 is selected from the group consisting of 2-Nal, Trp, 1-Me-Trp, 6-Cl-Trp, 3-(3-Quinolinyl)-Ala, Phe, 4-F-Phe, Glu, Cys, Ala, 6-F-Trp, His, 3-F-Phe, 3,4-Me-Phe, Bip, and {d}6-F-Trp;

X10 is selected from the group consisting of Leu, D-Leu, 2-Me-Leu, 2-Me-Lys, Trp, Asn, Cys, 4-aminotetrahydro-2H-pyran-4-acetyl, and 2-Me-Val;

X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, {d}2,4-diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl), D-Gln, D-Glu, D-His, 3-aminopropanoyl, and GABA, or is absent;

X13 is absent or is selected from the group consisting of Asn, Gly, 3-(3-Pyridyl)-Ala, 3-(4-Pyridyl)-Ala, 3-(3-Quinolinyl)-Ala, {d}[3-(3-Pyridyl)-Ala], 3-amino-3-(3'-pyridyl)propionyl, 3-F-Phe, 3,5-F-Phe, 4-aminomethyl-2-pyridineacetyl, 2,3-diaminopropanoyl(3-pyridylacetyl), 2,3-diaminopropanoyl(3-pyridylpropionyl), 2,3-diaminopropanoyl(3-fluorobenzoyl), 2,3-diaminopropanoyl(3-fluorophenylacetyl), and 2-Me-3-(3-Pyridyl)-Ala;

X14 is absent or is Gly;

X2 and X11 are amino acid residues who together form a lactam bridge, a dithioether bridge, or a bridge containing a triazole ring; and

X4 and X7 are amino acid residues who together form a lactam bridge, a dithioether bridge, or a bridge containing a triazole ring;

or a pharmaceutically acceptable salt or solvate thereof;

wherein the compound is not:

I3 (isomer 3) H-DC(1a)SC(2a)WQC(2a)WWLC(1a)R-[NH2];

wherein (1a) is a [2,11] 1,3-dithio-propan-2-one bridge and (2a) is a [4,7] 1,3-dithio-propan-2-one bridge.

2. The compound according to claim 1 of the formula:

$$R^1\text{-}Z\text{-}R^2$$

wherein

R^1 is H, $C_{1\text{-}4}$ acyl, benzoyl, $C_{1\text{-}4}$ alkyl, or is absent;

R^2 is NHR^3, OH, or is absent, wherein R^3 is hydrogen or $C_{1\text{-}3}$ alkyl; and

Z is an amino acid sequence of formula I:

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14 (I)

wherein

X1 is absent or is selected from the group consisting of Asp, Glu, Ser, Cys, and Lys;

X3 is selected from the group consisting of Ser, beta-homo-Ser, Thr, Leu, Cys, and Gln;

X5 is selected from the group consisting of Trp, Tyr, Ala, 1-Me-Trp, 7-Me-Trp, 7-Ph-Trp, 7-(Naphth-2-yl)-Trp, 2-Nal, and Bip;

X6 is selected from the group consisting of Gln, Glu, Tyr and Cys;

X8 is selected from the group consisting of Trp, Tyr, Asn, Ala, His, and 2-Nal, wherein the hydroxyl group of Tyr is optionally substituted with C_{1-3} alkyl optionally substituted with NH_2;

X9 is selected from the group consisting of 2-Nal, Trp, 1-Me-Trp, 6-Cl-Trp, 3-(3-Quinolinyl)-Ala, Phe, 4-F-Phe, Glu, Cys, and Ala;

X10 is selected from the group consisting of Leu, D-Leu, 2-Me-Leu, 2-Me-Lys, Trp, Asn, Cys, and 4-aminotetrahydro-2H-pyran-4-acetyl;

X12 is selected from the group consisting of Arg, D-Arg, 2-Me-Arg, N-Me-Arg, Ser, Phe, 4-NH_2-Phe, Tyr, Thr, Met, Gly, Glu, Asn, Dab, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala, or is absent;

X13 is absent or is selected from the group consisting of Asn, Gly, 3-(3-Pyridyl)-Ala, and 3-(4-Pyridyl)-Ala;

X14 is absent or is Gly;

X2 and X11 are amino acid residues who together form a lactam bridge, a dithioether bridge, or a bridge containing a triazole ring; and

X4 and X7 are amino acid residues who together form a lactam bridge, a dithioether bridge, or a bridge containing a triazole ring;

or a pharmaceutically acceptable salt or solvate thereof;

wherein the compound is not:

I3 (isomer 3) H-DC(1a)SC(2a)WQC(2a)WWLC(1a)R-[NH2];

wherein (1a) is a [2,11] 1,3-dithio-propan-2-one bridge and (2a) is a [4,7] 1,3-dithio-propan-2-one bridge.

3. The compound according to claim 1 or 2, wherein X1 is absent or Asp.

4. The compound according to any one of the preceding claims, wherein X1 is absent.

5. The compound according to any one of the preceding claims, wherein X2 and X11 are amino acid residues who together form a lactam bridge.

6. The compound according to claim 5, wherein the location of the amide bond in the lactam bridge is closer to X11 than X2.

7. The compound according to claim 5 or 6, wherein one of the residues at position X2 and X11 is selected from Lys, Arg, Orn, bAla, 3-(4-aminophenyl)propanoyl, (3-aminomethyl)benzoyl, (4-aminomethyl)benzoyl, 4-(2-aminoethyl)benzoyl, 2-aminomethyl-phenylacetyl, 3-aminomethyl-phenylacetyl, 4-aminomethyl-phenylacetyl, 4-aminomethyl-2-pyridineacetyl, 4-aminomethyl-3-pyridineacetyl, 4-aminomethyl-2-fluoro-phenylacetyl, 4-aminomethyl-3-fluoro-phenylacetyl, 4-aminomethyl-2-methyl-phenylacetyl, 4-aminomethyl-3-methyl-phenylacetyl, 4-aminomethyl-2-methoxy-phenylacetyl, 4-aminomethyl-3-methoxy-phenylacetyl, Dab, 6-aminohexanoyl, 6-amino-4-oxahexanoyl, trans-4-aminomethyl-cyclohexyl-1-carbonyl, (4-(2-aminoethyl)-piperazine-1-yl)-acetyl, 2,4-diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl), and 4-methylaminomethyl-phenylacetyl, and the other is selected from Glu and Asp.

8. The compound according to claim 7, wherein X2 is selected from Lys, Orn, bAla, 3-(4-aminophenyl)propanoyl, (3-aminomethyl)benzoyl, (4-aminomethyl)benzoyl, 4-(2-aminoethyl)benzoyl, 2-aminomethyl-phenylacetyl, 3-aminomethyl-phenylacetyl, 4-aminomethyl-phenylacetyl, 4-aminomethyl-2-pyridineacetyl, 4-aminomethyl-3-pyridineacetyl, 4-aminomethyl-2-fluoro-phenylacetyl, 4-aminomethyl-3-fluoro-phenylacetyl, 4-aminomethyl-2-methyl-phenylacetyl, 4-aminomethyl-3-methyl-phenylacetyl, 4-aminomethyl-2-methoxy-phenylacetyl, 4-aminomethyl-3-methoxy-phenylacetyl, 6-aminohexanoyl, 6-amino-4-oxahexanoyl, trans-4-aminomethyl-cyclohexyl-1-carbonyl, (4-(2-aminoethyl)-piperazine-1-yl)-acetyl, 2,4-diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl), and 4-methylaminomethyl-phenylacetyl, and X11 is selected from Glu and Asp.

9. The compound according to any one claims 1 to 4, wherein X2 and X11 are amino acid residues who together form a dithioether bridge.

10. The compound according to claim 9, wherein X2 and X11 are each independently selected from Cys and N-Me-Cys.

11. The compound according to claim 9 or 10, wherein X2 is Cys and X11 is Cys.

12. The compound according to any one of the preceding claims, wherein X4 and X7 are amino acid residues who together form a dithioether bridge.

13. The compound according to any one of claims 1 to 11, wherein X4 and X7 are amino acid residues who together form a lactam bridge.

14. The compound according to claim 13, wherein one of the residues at position X4 and X7 is Lys, Dpr, Dab, or Orn, and the other is Glu.

15. The compound according to claim 1 wherein Z is an amino acid sequence selected from the group consisting of:

SEQ ID NO: 1	DC(1a)SC(2a)WQC(2a)WW[2-Me-Leu]C(1a)R
SEQ ID NO: 2	LC(1a)SC(2a)WQC(2a)WWLC(1a)R
SEQ ID NO: 3	DC(1a)SC(2a)WEC(2a)WWLC(1a)R
SEQ ID NO: 4	DE(1c)SC(2a)WQC(2a)WWLK(1c)R
SEQ ID NO: 5	DC(1a)SE(2c)WQK(2c)WWLC(1a)R
SEQ ID NO: 6	D(1c)*SC(2a)WQC(2a)WWLR(1c)*
SEQ ID NO: 7	DK(1c)SC(2a)WQC(2a)WWLE(1c)R
SEQ ID NO: 8	D[Orn](1c)SC(2a)WQC(2a)WWLE(1c)R
SEQ ID NO: 9	DE(1c)SC(2a)WQC(2a)WWL[Dab](1c)R
SEQ ID NO: 10	E(1c)SC(2a)WQC(2a)WWLK(1c)R
SEQ ID NO: 11	DE(1c)SC(2a)WQC(2a)WWLK(1c)
SEQ ID NO: 12	E(1c)SC(2a)WQC(2a)WWLK(1c)
SEQ ID NO: 13	DE(1c)SC(2a)AQC(2a)WWLK(1c)R
SEQ ID NO: 14	DE(1c)SC(2a)WQC(2a)AWLK(1c)R
SEQ ID NO: 15	DE(1c)SC(2a)WQC(2a)WALK(1c)R
SEQ ID NO: 16	DE(1c)SC(2a)[7-Me-Trp]QC(2a)WWLK(1c)R
SEQ ID NO: 17	DE(1c)SC(2a)WQC(2a)W[2-Nal]LK(1c)R
SEQ ID NO: 18	K(1c)SC(2a)WQC(2a)W[2-Nal]LE(1c)R
SEQ ID NO: 19	DK(1c)SC(2a)WQC(2a)W[2-Nal]LE(1c)R
SEQ ID NO: 20	DK(1c)SC(2d)WQC(2d)W[2-Nal]LE(1c)R
SEQ ID NO: 21	DK(1c)SC(2e)WQC(2e)W[2-Nal]LE(1c)R
SEQ ID NO: 22	DK(1c)SC(2f)WQC(2f)W[2-Nal]LE(1c)R
SEQ ID NO: 23	DK(1c)S[K(N_3)](2g)WQ[Pra](2g)W[2-Nal]LE(1c)R
SEQ ID NO: 24	DK(1c)S[Aha](2g)WQ[Pra](2g)W[2-Nal]LE(1c)R

SEQ ID NO: 25	K(1c)SC(2a)[2-Nal]QC(2a)W[2-Nal]LE(1c)R
SEQ ID NO: 26	K(1c)SC(2a)[Bip]QC(2a)W[2-Nal]LE(1c)R
SEQ ID NO: 27	K(1c)SC(2a)[1-Me-Trp]QC(2a)W[2-Nal]LE(1c)R
SEQ ID NO: 28	DK(1c)SC(2a)WQC(2a)[2-Nal][2-Nal]LE(1c)R
SEQ ID NO: 29	K(1c)SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal]LE(1c)R
SEQ ID NO: 30	K(1c)SC(2a)WQC(2a)H[2-Nal]LE(1c)R
SEQ ID NO: 31	K(1c)SC(2a)WQC(2a)W[F(4-F)]LE(1c)R
SEQ ID NO: 32	K(1c)SC(2a)WQC(2a)W[1-Me-Trp]LE(1c)R
SEQ ID NO: 33	C(1a)TC(2a)WEC(2a)WW[2-Me-Leu]C(1a)S
SEQ ID NO: 34	GK(1c)TC(2a)WEC(2c)WW[2-Me-Leu]E(1c)S
SEQ ID NO: 35	GC(1a)TC(2a)WEC(2a)W[2-Nal][2-Me-Leu]C(1a)R
SEQ ID NO: 36	[bAla](1c)*SC(2a)WQC(2a)W[2-Nal]LE(1c)R
SEQ ID NO: 37	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)W[2-Nal]LE(1c)R
SEQ ID NO: 38	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
SEQ ID NO: 39	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal]LE(1c)R
SEQ ID NO: 40	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)W[2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 41	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 42	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[2-Me-Arg]
SEQ ID NO: 43	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[N-Me-Arg]
SEQ ID NO: 44	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)S
SEQ ID NO: 45	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[F(4-NH_2)]
SEQ ID NO: 46	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][{d}L]E(1c)Y
SEQ ID NO: 47	[Ac]-K(1c)SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 48	[Ac]-K(1c)SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][{d}L]E(1c)R
SEQ ID NO: 49	[(4-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R

SEQ ID NO: 50	[4-(2-Aminoethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 51	[3-(4-Aminophenyl)propanoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 52	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 53	DC(1a)SC(2b)WQC(2b)WWLC(1a)R
SEQ ID NO: 54	K(1c)SC(2b)WQC(2b)[Y(2-aminoethoxy)][2-Nal]LE(1c)R
SEQ ID NO: 55	DE(1c)QC(2a)WQC(2a)YW[2-Me-Leu]K(1c)R
SEQ ID NO: 56	DE(1c)QC(2a)WQC(2a)[2-Nal]W[2-Me-Leu]K(1c)R
SEQ ID NO: 57	DE(1c)TC(2a)WQC(2a)W[2-Nal][2-Me-Leu]K(1c)
SEQ ID NO: 58	DE(1c)SC(2a)WQC(2a)W[2-Nal][2-Me-Leu]K(1c)ENG
SEQ ID NO: 59	DE(1c)SC(2a)WQC(2a)W[2-Nal][2-Me-Leu]K(1c)NG
SEQ ID NO: 60	DE(1c)SC(2a)WQC(2a)W[2-Nal][2-Me-Leu]K(1c)G
SEQ ID NO: 61	DE(1c)SC(2a)WQC(2a)W[2-Nal][2-Me-Lys]K(1c)ENG
SEQ ID NO: 62	DC(1a)QC(2a)WQC(2a)[2-Nal]W[2-Me-Leu]C(1a)R
SEQ ID NO: 63	DC(1a)QC(2a)WQC(2a)YW[2-Me-Leu]C(1a)R
SEQ ID NO: 64	DC(1a)QC(2a)WQC(2a)WW[2-Me-Leu]C(1a)ENG
SEQ ID NO: 65	[(3-Aminomethyl)benzoyl](1c)*S[Dpr](2c)WQE(2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 66	[(3-Aminomethyl)benzoyl](1c)*SE(2c)WQ[Dpr](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 67	[(3-Aminomethyl)benzoyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 68	[(3-Aminomethyl)benzoyl](1c)*S[Orn](2c)WQE(2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 69	[(3-Aminomethyl)benzoyl](1c)*SE(2c)WQ[Orn](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 70	[(3-Aminomethyl)benzoyl](1c)*SC(2a)[7-Me-Trp]QC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 71	[(3-Aminomethyl)benzoyl](1c)*SC(2a)[7-Ph-Trp]QC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R
SEQ ID NO: 72	[(3-Aminomethyl)benzoyl](1c)*SC(2a)[7-(Naphth-2-yl)-Trp]QC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R

SEQ ID NO: 73	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][3-(3-Quinolinyl)-Ala][2-Me-Leu]E(1c)R
SEQ ID NO: 74	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][6-Cl-Trp][2-Me-Leu]E(1c)R
SEQ ID NO: 75	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][4-aminotetrahydro-2H-pyran-4-acetyl]E(1c)R
SEQ ID NO: 76	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-(3-Pyridyl)-Ala]
SEQ ID NO: 77	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-(4-Pyridyl)-Ala]
SEQ ID NO: 78	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[3-(3-Pyridyl)-Ala]
SEQ ID NO: 79	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[3-(4-Pyridyl)-Ala]
SEQ ID NO: 80	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 81	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)S
SEQ ID NO: 82	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 83	[4-Aminomethyl-phenylacetyl](1c)*TC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 84	K(1c)SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 85	K(1c)TC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 86	K(1c)SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)S
SEQ ID NO: 87	[6-Aminohexanoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 88	[6-Amino-4-oxahexanoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 89	[trans-4-Aminomethyl-cyclohexyl-1-carbonyl](1c)*[beta-homo-Ser]C(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 90	[(4-(2-Aminoethyl)-piperazine-1-yl)-acetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 91	[(4-(2-Aminoethyl)-piperazine-1-yl)-acetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]D(1c)[{d}R]
SEQ ID NO: 92	[3-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]

SEQ ID NO: 93	[2-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 94	[K(N_3)](1g)SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Pra](1g)[{d}R]
SEQ ID NO: 95	[Azidoacetic acid](1g)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Glu(propargylamine)](1g)[{d}R]
SEQ ID NO: 96	[Azidoacetic acid](1g)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab(3-butynoic acid)](1g)[{d}R]
SEQ ID NO: 97	[but-3-ynoic acid](1g)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab(azidoacetic acid)](1g)[{d}R]
SEQ ID NO: 98	[(N_3)-Ala](1g)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Glu(propargylamine)](1g)[{d}R]
SEQ ID NO: 99	[(N_3)-Ala](1g)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab(3-butynoic acid)](1g)[{d}R]
SEQ ID NO: 100	[but-3-ynoic acid](1g)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab((N_3)-Ala))](1g)[{d}R]
SEQ ID NO: 101	[4-Aminomethyl-2-pyridineacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 102	[4-Aminomethyl-3-pyridineacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 103	[4-Aminomethyl-2-fluoro-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 104	[4-Aminomethyl-3-methyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 105	[4-Aminomethyl-3-methoxy-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 106	[but-3-ynoic acid](1h)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab(azidoacetic acid)](1h)[{d}R]
SEQ ID NO: 107	[but-3-ynoic acid](1h)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab((N3)-Ala)](1h)[{d}R]
SEQ ID NO: 108	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 109	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}2,4-Diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl)]
SEQ ID NO: 110	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Dab][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 111	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[2,4-Diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl)][2-Nal][2-Me-Leu]E(1c)[{d}R]

SEQ ID NO: 112	[Dab](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 113	[2,4-Diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl)](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 114	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[F(4-NH2-(2-(trimethyl-2-aminoethoxy)ethoxy)propyl)][2-Nal][2-Me-Leu]E(1c)[{d}R]
SEQ ID NO: 115	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}Q]
SEQ ID NO: 116	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}E]
SEQ ID NO: 117	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}H]
SEQ ID NO: 118	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-Aminopropanoyl]
SEQ ID NO: 119	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-Aminopropanoyl]
SEQ ID NO: 120	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]
SEQ ID NO: 121	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][6-F-Trp][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]
SEQ ID NO: 122	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]
SEQ ID NO: 123	[4-Aminomethyl-phenylacetyl](1c)*S[Dab](2c)WQE(2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]
SEQ ID NO: 124	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Orn](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]
SEQ ID NO: 125	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 126	[4-Aminomethyl-phenylacetyl](1c)*VE(2c)WQ[Dab](2c)[Y(2-aminoethoxy][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 127	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 128	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WV[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 129	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WH[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 130	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)F[2-Nal][2-Me-Leu]E(1c)[Dab]

SEQ ID NO: 131	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)V[2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 132	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[F(4-Me)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 133	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)]H[2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 134	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][F(3-F)][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 135	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][F(3,4-Me)][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 136	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)[Dab]
SEQ ID NO: 137	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)
SEQ ID NO: 138	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)[4-F-Trp]Q[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 139	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)[7-F-Trp]Q[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 140	[4-Methylaminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 141	[4-Aminomethyl-phenylacetyl](1c)*[N-Me-Ser]C(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 142	[4-Aminomethyl-phenylacetyl](1c)*S[N-Me-Cys](2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 143	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)[N-Me-Trp]QC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 144	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)W[N-Me-Gln]C(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 145	[4-Aminomethyl-phenylacetyl](1c)*[Q(pyrrolidin)]E(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 146	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)W[Q(pyrrolidin)][Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]
SEQ ID NO: 147	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[3-(3-Pyridyl)-Ala]
SEQ ID NO: 148	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]
SEQ ID NO: 149	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)][Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[3-(3-Quinolinyl)-Ala]

SEQ ID NO: 150	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)][Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[{d}[3-(3-Pyridyl)-Ala]]
SEQ ID NO: 151	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)][Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[3-Amino-3-(3'-pyridyl)propionyl]
SEQ ID NO: 152	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)][Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[F(3-F)]
SEQ ID NO: 153	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)][Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[F(3,5-F)]
SEQ ID NO: 154	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)][Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[4-Aminomethyl-2-pyridineacetyl]
SEQ ID NO: 155	K(1c)TC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]
SEQ ID NO: 156	[(3-Aminomethyl)benzoyl](1c)*IE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)[Dab][3-(3-Pyridyl)-Ala]
SEQ ID NO: 157	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)[Dab][3-(3-Pyridyl)-Ala]
SEQ ID NO: 158	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][F(3,4-Me)][2-Me-Val]E(1c)G[3-(3-Pyridyl)-Ala]
SEQ ID NO: 159	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][F(3,4-Me)][2-Me-Val]E(1c)G[3-(3-Pyridyl)-Ala]
SEQ ID NO: 160	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][F(3,4-Me)][2-Me-Val]E(1c)[GABA][3-(3-Pyridyl)-Ala]
SEQ ID NO: 161	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][F(3,4-Me)][2-Me-Val]E(1c)G[2,3-Diaminopropanoyl(3-pyridylacetyl)]
SEQ ID NO: 162	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][F(3,4-Me)][2-Me-Val]E(1c)G[2,3-Diaminopropanoyl(3-pyridylpropionyl)]
SEQ ID NO: 163	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][F(3,4-Me)][2-Me-Val]E(1c)G[2,3-Diaminopropanoyl(3-fluorobenzoyl)]
SEQ ID NO: 164	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][F(3,4-Me)][2-Me-Val]E(1c)G[2,3-Diaminopropanoyl(3-fluorophenylacetyl)]
SEQ ID NO: 165	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]
SEQ ID NO: 166	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Y(Me)][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]
SEQ ID NO: 167	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[2-Me-Phe][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]
SEQ ID NO: 168	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Bip][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]

SEQ ID NO: 169	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[2-Me-F(4-F)][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]
SEQ ID NO: 170	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[{d}F(4-F)][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]
SEQ ID NO: 171	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Cl)][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]
SEQ ID NO: 172	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[alpha-Me-Trp][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]
SEQ ID NO: 173	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[3,3-Diphenyl-Ala][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]
SEQ ID NO: 174	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Phg][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]
SEQ ID NO: 175	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][1-Me-Trp][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]
SEQ ID NO: 176	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][Bip][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]
SEQ ID NO: 177	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][{d}6-F-Trp][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]

or a pharmaceutically acceptable salt or solvate thereof;

wherein:

* = bridge uses the peptide backbone amine or carboxylic acid at the *N*- or *C*-terminus, not the side chain amine or carboxylic acid

(1a) = [2,11] 1,3-dithio-propan-2-one bridge; (1c) = [2,11] lactam bridge; (1g) = [2,11] 1,4-disubstituted 1,2,3-triazole bridge; (1h) = [2,11] 1,5-disubstituted 1,2,3-triazole bridge; (2a) = [4,7] 1,3-dithio-propan-2-one bridge; (2c) = [4,7] lactam bridge; (2d) = [4,7] 1,2-phenylenedimethanethiol bridge; (2e) = [4,7] 1,3-phenylenedimethanethiol bridge; (2f) = [4,7] 1,4-phenylenedimethanethiol bridge; (2g) = [4,7] 1,4-disubstituted 1,2,3-triazole bridge.

16. A compound according to claim 1 which is selected from:

1	H-DC(1a)SC(2a)WQC(2a)WW[2-Me-Leu]C(1a)R-[NH2]
2	H-LC(1a)SC(2a)WQC(2a)WWLC(1a)R-[NH2]

3	H-DC(1a)SC(2a)WEC(2a)WWLC(1a)R-[NH2]
4	H-DE(1c)SC(2a)WQC(2a)WWLK(1c)R-[NH2]
5	H-DC(1a)SE(2c)WQK(2c)WWLC(1a)R-[NH2]
6	D(1c)*SC(2a)WQC(2a)WWLR(1c)*
7	[Ac]-DK(1c)SC(2a)WQC(2a)WWLE(1c)R-[NH2]
8	[Ac]-D[Orn](1c)SC(2a)WQC(2a)WWLE(1c)R-[NH2]
9	H-DE(1c)SC(2a)WQC(2a)WWL[Dab](1c)R-[NH2]
10	[Ac]-E(1c)SC(2a)WQC(2a)WWLK(1c)R-[NH2]
11	[Ac]-DE(1c)SC(2a)WQC(2a)WWLK(1c)-[NH2]
12	[Ac]-E(1c)SC(2a)WQC(2a)WWLK(1c)-[NH2]
13	[Ac]-DE(1c)SC(2a)AQC(2a)WWLK(1c)R-[NH2]
14	[Ac]-DE(1c)SC(2a)WQC(2a)AWLK(1c)R-[NH2]
15	[Ac]-DE(1c)SC(2a)WQC(2a)WALK(1c)R-[NH2]
16	[Ac]-DE(1c)SC(2a)[7-Me-Trp]QC(2a)WWLK(1c)R-[NH2]
17	[Ac]-DE(1c)SC(2a)WQC(2a)W[2-Nal]LK(1c)R-[NH2]
18	[Ac]-K(1c)SC(2a)WQC(2a)W[2-Nal]LE(1c)R-[NH2]
19	[Ac]-DK(1c)SC(2a)WQC(2a)W[2-Nal]LE(1c)R-[NH2]
20	[Ac]-DK(1c)SC(2d)WQC(2d)W[2-Nal]LE(1c)R-[NH2]
21	[Ac]-DK(1c)SC(2e)WQC(2e)W[2-Nal]LE(1c)R-[NH2]

22	[Ac]-DK(1c)SC(2f)WQC(2f)W[2-Nal]LE(1c)R-[NH2]
23	[Ac]-DK(1c)S[K(N_3)](2g)WQ[Pra](2g)W[2-Nal]LE(1c)R-[NH2]
24	[Ac]-DK(1c)S[Aha](2g)WQ[Pra](2g)W[2-Nal]LE(1c)R-[NH2]
25	[Ac]-K(1c)SC(2a)[2-Nal]QC(2a)W[2-Nal]LE(1c)R-[NH2]
26	[Ac]-K(1c)SC(2a)[Bip]QC(2a)W[2-Nal]LE(1c)R-[NH2]
27	[Ac]-K(1c)SC(2a)[1-Me-Trp]QC(2a)W[2-Nal]LE(1c)R-[NH2]
28	[Ac]-DK(1c)SC(2a)WQC(2a)[2-Nal][2-Nal]LE(1c)R-[NH2]
29	[Ac]-K(1c)SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal]LE(1c)R-[NH2]
30	[Ac]-K(1c)SC(2a)WQC(2a)H[2-Nal]LE(1c)R-[NH2]
31	[Ac]-K(1c)SC(2a)WQC(2a)W[F(4-F)]LE(1c)R-[NH2]
32	[Ac]-K(1c)SC(2a)WQC(2a)W[1-Me-Trp]LE(1c)R-[NH2]
33	[Ac]-C(1a)TC(2a)WEC(2a)WW[2-Me-Leu]C(1a)S-[NH2]
34	[Ac]-GK(1c)TC(2a)WEC(2c)WW[2-Me-Leu]E(1c)S-[NH2]
35	[Ac]-GC(1a)TC(2a)WEC(2a)W[2-Nal][2-Me-Leu]C(1a)R-[NH2]
36	[bAla](1c)*SC(2a)WQC(2a)W[2-Nal]LE(1c)R-[NH2]
37	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)W[2-Nal]LE(1c)R-[NH2]
38	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
39	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal]LE(1c)R-[NH2]

40	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)W[2-Nal][2-Me-Leu]E(1c)R-[NH2]
41	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
42	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[2-Me-Arg]-[NH2]
43	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[N-Me-Arg]-[NH2]
44	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)S-[NH2]
45	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[F(4-NH_2)]-[NH2]
46	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][{d}L]E(1c)Y-[NH2]
47	[Ac]-K(1c)SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
48	[Ac]-K(1c)SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][{d}L]E(1c)R-[NH2]
49	[(4-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
50	[4-(2-Aminoethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
51	[3-(4-Aminophenyl)propanoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
52	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
53	H-DC(1a)SC(2b)WQC(2b)WWLC(1a)R-[NH2]
54	[Ac]-K(1c)SC(2b)WQC(2b)[Y(2-aminoethoxy)][2-Nal]LE(1c)R-[NH2]

55	[Ac]-DE(1c)QC(2a)WQC(2a)YW[2-Me-Leu]K(1c)R-[NH2]
56	[Ac]-DE(1c)QC(2a)WQC(2a)[2-Nal]W[2-Me-Leu]K(1c)R-[NH2]
57	[Ac]-DE(1c)TC(2a)WQC(2a)W[2-Nal][2-Me-Leu]K(1c)R-[NH2]
58	[Ac]-DE(1c)SC(2a)WQC(2a)W[2-Nal][2-Me-Leu]K(1c)ENG-[NH2]
59	[Ac]-DE(1c)SC(2a)WQC(2a)W[2-Nal][2-Me-Leu]K(1c)NG-[NH2]
60	[Ac]-DE(1c)SC(2a)WQC(2a)W[2-Nal][2-Me-Leu]K(1c)G-[NH2]
61	[Ac]-DE(1c)SC(2a)WQC(2a)W[2-Nal][2-Me-Lys]K(1c)ENG-[NH2]
62	[Ac]-DC(1a)QC(2a)WQC(2a)[2-Nal]W[2-Me-Leu]C(1a)R-[NH2]
63	[Ac]-DC(1a)QC(2a)WQC(2a)YW[2-Me-Leu]C(1a)R-[NH2]
64	[Ac]-DC(1a)QC(2a)WQC(2a)WW[2-Me-Leu]C(1a)ENG-[NH2]
65	[(3-Aminomethyl)benzoyl](1c)*S[Dpr](2c)WQE(2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
66	[(3-Aminomethyl)benzoyl](1c)*SE(2c)WQ[Dpr](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
67	[(3-Aminomethyl)benzoyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
68	[(3-Aminomethyl)benzoyl](1c)*S[Orn](2c)WQE(2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
69	[(3-Aminomethyl)benzoyl](1c)*SE(2c)WQ[Orn](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
70	[(3-Aminomethyl)benzoyl](1c)*SC(2a)[7-Me-Trp]QC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
71	[(3-Aminomethyl)benzoyl](1c)*SC(2a)[7-Ph-Trp]QC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]

72	[(3-Aminomethyl)benzoyl](1c)*SC(2a)[7-(Naphth-2-yl)-Trp]QC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R-[NH2]
73	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][3-(3-Quinolinyl)-Ala][2-Me-Leu]E(1c)R-[NH2]
74	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][6-Cl-Trp][2-Me-Leu]E(1c)R-[NH2]
75	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][4-aminotetrahydro-2H-pyran-4-acetyl]E(1c)R-[NH2]
76	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-(3-Pyridyl)-Ala]-[NH2]
77	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-(4-Pyridyl)-Ala]-[NH2]
78	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[3-(3-Pyridyl)-Ala]-[NH2]
79	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[3-(4-Pyridyl)-Ala]-[NH2]
80	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
81	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)S-[NH2]
82	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
83	[4-Aminomethyl-phenylacetyl](1c)*TC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
84	[Ac]-K(1c)SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
85	[Ac]-K(1c)TC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]

86	[Ac]-K(1c)SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)S-[NH2]
87	[6-Aminohexanoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
88	[6-Amino-4-oxahexanoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
89	[trans-4-Aminomethyl-cyclohexyl-1-carbonyl](1c)*[beta-homo-Ser]C(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
90	[(4-(2-Aminoethyl)-piperazine-1-yl)-acetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
91	[(4-(2-Aminoethyl)-piperazine-1-yl)-acetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]D(1c)[{d}R]-[NH2]
92	[3-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
93	[2-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
94	[Ac]-[K(N_3)](1g)SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Pra](1g)[{d}R]-[NH2]
95	[Azidoacetic acid](1g)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Glu(propargylamine)](1g)[{d}R]-[NH2]
96	[Azidoacetic acid](1g)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab(3-butynoic acid)](1g)[{d}R]-[NH2]
97	[but-3-ynoic acid](1g)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab(azidoacetic acid)](1g)[{d}R]-[NH2]
98	[(N_3)-Ala](1g)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Glu(propargylamine)](1g)[{d}R]-[NH2]
99	[(N_3)-Ala](1g)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab(3-butynoic acid)](1g)[{d}R]-[NH2]

100	[but-3-ynoic acid](1g)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab((N3)-Ala))](1g)[{d}R]-[NH2]
101	[4-Aminomethyl-2-pyridineacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
102	[4-Aminomethyl-3-pyridineacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
103	[4-Aminomethyl-2-fluoro-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
104	[4-Aminomethyl-3-methyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
105	[4-Aminomethyl-3-methoxy-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
106	[but-3-ynoic acid](1h)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab(azidoacetic acid)](1h)[{d}R]-[NH2]
107	[but-3-ynoic acid](1h)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu][Dab((N3)-Ala))](1h)[{d}R]-[NH2]
108	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[OH]
109	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}2,4-Diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl)]-[NH2]
110	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Dab][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
111	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[2,4-Diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
112	[Dab](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]

113	[2,4-Diaminobutanoyl([2-(trimethyl-2-aminoethoxy)ethoxy]propyl)](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
114	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[F(4-NH2-(2-(trimethyl-2-aminoethoxy)ethoxy)propyl)][2-Nal][2-Me-Leu]E(1c)[{d}R]-[NH2]
115	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}Q]-[NH2]
116	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}E]-[NH2]
117	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[{d}H]-[NH2]
118	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-Aminopropanoyl]-[OH]
119	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[3-Aminopropanoyl]-[NH2]
120	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]
121	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][6-F-Trp][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]
122	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]
123	[4-Aminomethyl-phenylacetyl](1c)*S[Dab](2c)WQE(2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]
124	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Orn](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]
125	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
126	[4-Aminomethyl-phenylacetyl](1c)*VE(2c)WQ[Dab](2c)[Y(2-aminoethoxy][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]

127	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
128	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WV[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
129	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WH[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
130	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)F[2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
131	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)V[2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
132	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[F(4-Me)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
133	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)]H[2-Me-Leu]E(1c)[Dab]-[NH2]
134	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][F(3-F)][2-Me-Leu]E(1c)[Dab]-[NH2]
135	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][F(3,4-Me)][2-Me-Leu]E(1c)[Dab]-[NH2]
136	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)[Dab]-[NH2]
137	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)-[NH-3-aminopropanoyl]
138	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)[4-F-Trp]Q[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
139	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)[7-F-Trp]Q[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
140	[4-Methylaminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]

141	[4-Aminomethyl-phenylacetyl](1c)*[N-Me-Ser]C(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
142	[4-Aminomethyl-phenylacetyl](1c)*S[N-Me-Cys](2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
143	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)[N-Me-Trp]QC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
144	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)W[N-Me-Gln]C(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
145	[4-Aminomethyl-phenylacetyl](1c)*[Q(pyrrolidin)]E(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
146	[4-Aminomethyl-phenylacetyl](1c)*SE(2c)W[Q(pyrrolidin)][Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab]-[NH2]
147	[4-Aminomethyl-phenylacetyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[3-(3-Pyridyl)-Ala]-[NH2]
148	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]
149	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)][Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[3-(3-Quinolinyl)-Ala]-[NH2]
150	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)][Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[{d}[3-(3-Pyridyl)-Ala]]-[NH2]
151	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)][Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[3-Amino-3-(3'-pyridyl)propionyl]-[NH2]
152	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)][Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[F(3-F)]-[NH2]
153	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)][Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[F(3,5-F)]-[NH2]
154	[(3-Aminomethyl)benzoyl](1c)*SC(2a)WQC(2a)][Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)R[4-Aminomethyl-2-pyridineacetyl]-[NH2]

155	[Ac]-K(1c)TC(2a)WQC(2a)[Y(2-aminoethoxy)][2-Nal][2-Me-Leu]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]
156	[(3-Aminomethyl)benzoyl](1c)*IE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]
157	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][2-Nal][2-Me-Val]E(1c)[Dab][3-(3-Pyridyl)-Ala]-[NH2]
158	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][F(3,4-Me)][2-Me-Val]E(1c)G[3-(3-Pyridyl)-Ala]-[NH2]
159	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][F(3,4-Me)][2-Me-Val]E(1c)G[3-(3-Pyridyl)-Ala]-[NH2]
160	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][F(3,4-Me)][2-Me-Val]E(1c)[GABA][3-(3-Pyridyl)-Ala]-[NH2]
161	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][F(3,4-Me)][2-Me-Val]E(1c)G[2,3-Diaminopropanoyl(3-pyridylacetyl)]-[NH2]
162	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][F(3,4-Me)][2-Me-Val]E(1c)G[2,3-Diaminopropanoyl(3-pyridylpropionyl)]-[NH2]
163	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][F(3,4-Me)][2-Me-Val]E(1c)G[2,3-Diaminopropanoyl(3-fluorobenzoyl)]-[NH2]
164	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][F(3,4-Me)][2-Me-Val]E(1c)G[2,3-Diaminopropanoyl(3-fluorophenylacetyl)]-[NH2]
165	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Y(2-aminoethoxy)][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
166	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Y(Me)][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
167	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[2-Me-Phe][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
168	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Bip][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]

169	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[2-Me-F(4-F)][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
170	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[{d}F(4-F)][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
171	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Cl)][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
172	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[alpha-Me-Trp][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
173	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[3,3-Diphenyl-Ala][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
174	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[Phg][F(3,4-Me)][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
175	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][1-Me-Trp][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
176	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][Bip][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]
177	[4-Aminomethyl-phenylacetyl](1c)*IE(2c)WQ[Dab](2c)[F(4-Me)][{d}6-F-Trp][2-Me-Val]E(1c)[Dab][2-Me-3-(3-Pyridyl)-Ala]-[NH2]

and pharmaceutically acceptable salts and solvates thereof;

wherein:

* = bridge uses the peptide backbone amine or carboxylic acid at the *N*- or *C*-terminus, not the side chain amine or carboxylic acid

(1a) = [2,11] 1,3-dithio-propan-2-one bridge; (1c) = [2,11] lactam bridge; (1g) = [2,11] 1,4-disubstituted 1,2,3-triazole bridge; (1h) = [2,11] 1,5-disubstituted 1,2,3-triazole bridge; (2a) = [4,7] 1,3-dithio-propan-2-one bridge; (2c) = [4,7] lactam bridge; (2d) = [4,7] 1,2-phenylenedimethanethiol bridge; (2e) = [4,7] 1,3-phenylenedimethanethiol bridge; (2f) = [4,7] 1,4-phenylenedimethanethiol bridge; (2g) = [4,7] 1,4-disubstituted 1,2,3-triazole bridge.

17. A pharmaceutical composition comprising a compound according to any one of the preceding claims in combination with a pharmaceutically acceptable carrier, excipient or vehicle.

18. A compound according to any one of claims 1 to 16, or a pharmaceutical composition according to claim 17, for use in a method of medical treatment.

19. Use of a compound according to any one of claims 1 to 16, or a pharmaceutical composition according to claim 17, in the manufacture of a medicament for the prevention or treatment of Inflammatory Bowel Disease (IBD), ulcerative colitis, Crohn's disease, Celiac disease (nontropical Sprue), enteropathy associated with seronegative arthropathies, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-I, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, and Wiskott-Aldrich Syndrome, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, psoriasis, psoriatic arthritis, ankylosing spondylitis, or graft versus host disease in a subject, and combinations thereof.

20. The use according to claim 19, wherein the medicament is for the prevention or treatment of inflammatory bowel (IBD), Crohn’s Disease, ulcerative colitis, and psoriasis.